Ichthyosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ichthyosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Injectable Gentamicin for Patients with Moderate to Severe Congenital Ichthyosis https://clinicaltrials.eu/trial/study-on-the-effects-of-injectable-gentamicin-for-patients-with-moderate-to-severe-congenital-ichthyosis/ Wed, 29 Apr 2026 14:57:16 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-injectable-gentamicin-for-patients-with-moderate-to-severe-congenital-ichthyosis/ This clinical trial is focused on studying a skin condition called congenital ichthyosis, which is a group of genetic disorders that cause dry, scaly skin. The study is investigating the use of a medication called gentamicin, which is given as an injection. Gentamicin is typically used to treat infections, but in this study, it is being tested to see if it can help reduce the severity of skin scales and redness in people with moderate to severe congenital ichthyosis caused by a specific type of genetic change known as a nonsense mutation.

The purpose of the study is to evaluate how effective gentamicin is in improving the skin condition over a period of time. Participants in the study will receive injections of gentamicin and will be monitored for changes in their skin condition. The study will track the severity of the skin scales and redness at different times to see if there is any improvement. Participants will also be asked about their experience with itching and their overall quality of life during the study.

Throughout the study, various assessments will be conducted to ensure the safety and well-being of the participants. These assessments include checking kidney function, hearing, and balance, as well as collecting information on any side effects experienced. The study aims to provide valuable information on whether gentamicin can be a beneficial treatment for people with congenital ichthyosis.

]]> Study on the Effects of Deucravacitinib for Adults with Inflammatory Skin Conditions (Epidermolysis Bullosa Simplex and Congenital Ichthyoses) https://clinicaltrials.eu/trial/study-on-the-effects-of-deucravacitinib-for-adults-with-inflammatory-skin-conditions-epidermolysis-bullosa-simplex-and-congenital-ichthyoses/ Wed, 29 Apr 2026 14:26:48 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-deucravacitinib-for-adults-with-inflammatory-skin-conditions-epidermolysis-bullosa-simplex-and-congenital-ichthyoses/ This clinical trial is focused on studying the effects of a medication called deucravacitinib in adults with certain skin conditions known as inflammatory epidermal genodermatoses. These conditions include epidermolysis bullosa simplex and inflammatory congenital ichthyoses. The purpose of the study is to evaluate how effective and safe deucravacitinib is for treating these skin conditions.

Participants in the study will take deucravacitinib, which is provided in the form of a 6 mg film-coated tablet, taken orally. The study will last for 44 weeks and will follow a specific pattern where the medication is given, then stopped, and then given again. This approach helps researchers understand how the medication works over time. The study will also look at how the medication affects the severity of the skin conditions, the level of itch and pain experienced, and the overall quality of life of the participants.

Throughout the study, the safety of deucravacitinib will be closely monitored. Researchers will also collect information on how well participants follow the treatment plan and will analyze certain proteins in the body, known as cytokines, to understand their role in these skin conditions. The study aims to provide valuable insights into the potential benefits of deucravacitinib for people living with these challenging skin disorders.

]]>